Tyra Biosciences (NASDAQ:TYRA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Tyra Biosciences (NASDAQ:TYRA – Free Report) from a sell rating to a hold rating in a research note released on Sunday.

Other analysts also recently issued reports about the stock. Wedbush boosted their target price on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.20.

Read Our Latest Stock Analysis on TYRA

Tyra Biosciences Stock Up 0.4%

Shares of Tyra Biosciences stock opened at $26.40 on Friday. The business has a fifty day simple moving average of $20.93 and a 200-day simple moving average of $15.06. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $27.66. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -14.12 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). Analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. The trade was a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TYRA. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Tyra Biosciences by 23.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock valued at $2,807,000 after buying an additional 57,556 shares during the last quarter. Polar Asset Management Partners Inc. raised its position in Tyra Biosciences by 27.1% during the first quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock valued at $1,314,000 after acquiring an additional 30,134 shares in the last quarter. Corton Capital Inc. acquired a new stake in Tyra Biosciences in the second quarter valued at approximately $233,000. Dynamic Technology Lab Private Ltd bought a new stake in Tyra Biosciences in the second quarter worth approximately $326,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth $177,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

Featured Stories